"Phase 1 clinical trials of a 15-PGDH inhibitor for muscle weakness have shown that it is safe and active in healthy volunteers. Our hope is that a similar trial will be launched soon to test its effect in cartilage regeneration" - Helen Blau, Baxter Laboratory for Stem Cell Biology & the Donald E. and Delia B. Baxter Foundation Professorship

▲

mobilejdral 5 hours ago | parent [-]

ERa activation promotes PGE2 resulting in decreased 15-PGDH.

So this is one of those standard poor estrogen signaling downstream things and simply improving the estrogen signaling and you get improved cartilage. Anyone can do this today along with getting all of the other positive effects. Those with EDS who have say variants on their TNXA/B have poor production ability to start and so we do everything we can to improve their cartilage production as they can only make so much which include doing stuff like this.

▲

amluto 4 hours ago | parent | next [-]

> Anyone can do this today

Please explain

	▲	mobilejdral 30 minutes ago \| parent \| next [-]
		It depends on the person and their genetics. The further you get from the ERa the more complicated this gets and simply stating "Do X" wouldn't apply to everyone even if there are some incredibly common things to do. I might know all the upstream genes, their interactions, and symptoms by heart so it is pretty easy to identify, but general advice would go something like: eat well, get sleep and exercise.
	▲	RealityVoid 3 hours ago \| parent \| prev [-]
		Yes, I deff want this explained, since I'm missing about half of my meniscus.

▲

shermantanktop 4 hours ago | parent | prev [-]

EDS and arthritis go together so I wonder if we could see secondary effects on other EDS symptoms like subluxation or GI issues?